You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK tyrosine kinase receptor

Showing 1 - 25 of 9,744
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • +5 more
  • Orange, California
  • +13 more
Nov 7, 2022

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure

Completed
  • Non-small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Sep 23, 2021

Liposarcoma, Metastatic Liposarcoma Trial in Boston, Saint Louis, New York (MGCD516)

Active, not recruiting
  • Liposarcoma
  • Metastatic Liposarcoma
  • Boston, Massachusetts
  • +2 more
Nov 23, 2022

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

NSCLC Trial in Germany (Brigatinib, Tyrosine kinase inhibitor)

Recruiting
  • NSCLC
  • Berlin, Germany
  • +25 more
Nov 10, 2022

A Retro-/Prospective, Non-interventional, Cohort Study in Adult

Active, not recruiting
  • Solid Tumor, Adult
  • +2 more
    • Amiens, France
    • +3 more
    Jul 22, 2022

    Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

    Recruiting
    • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
    • Topical Timolol
    • Hong Kong, Hong Kong
      Queen Mary Hospital
    Nov 14, 2023

    Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

    Withdrawn
    • Non-Small Cell Lung Cancer
    • InVisionFirst-Lung ctDNA assay
    • Los Angeles, California
    • +2 more
    Sep 16, 2022

    NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +2 more
    • (no location specified)
    Mar 27, 2023

    MuSK Myasthenia Gravis Trial (MuSK-CAART)

    Not yet recruiting
    • MuSK Myasthenia Gravis
    • MuSK-CAART
    • (no location specified)
    Jul 5, 2022

    Advanced Non Small Cell Lung Cancer Trial in Changchun, Shanghai, Hangzhou (D-0316)

    Active, not recruiting
    • Advanced Non Small Cell Lung Cancer
    • Changchun, Jilin, China
    • +2 more
    Apr 29, 2022

    Myasthenia Gravis, MuSK Trial in Cleveland, Philadelphia (Amifampridine Phosphate)

    Active, not recruiting
    • Myasthenia Gravis, MuSK
    • Amifampridine Phosphate
    • Cleveland, Ohio
    • +1 more
    Jul 21, 2022

    NSCLC ALK-positive, NSCLC c-Met Dependent, NSCLC ROS Marker Positive Trial in Worldwide (PF-02341066, Rifampin, Itraconazole)

    Completed
    Has Results
    • Non-Small Cell Lung Cancer ALK-positive
    • +4 more
    • Orange, California
    • +28 more
    Feb 15, 2022

    NSCLC Stage IV Trial in Taipei (therapeutic thoracic surgery, Afatinib)

    Recruiting
    • NSCLC Stage IV
    • Taipei, Taiwan
    • +1 more
    Mar 8, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

    Active, not recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +2 more
    • Duarte, California
    • +14 more
    Jan 27, 2023

    NSCLC Trial in Australia, China, Korea, Republic of (AZD9291)

    Active, not recruiting
    Has Results
    • Non-Small Cell Lung Cancer
    • Kogarah, Australia
    • +29 more
    Oct 20, 2022

    Stage II Renal Cell Cancer, Stage III Renal Cell Cancer Trial (tivozanib, therapeutic conventional surgery)

    Withdrawn
    • Stage II Renal Cell Cancer
    • Stage III Renal Cell Cancer
    • (no location specified)
    Aug 11, 2022

    NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 23, 2023

    Carcinoma, Non-Small-Cell Lung Trial in Worldwide (Lorlatinib)

    Recruiting
    • Carcinoma
    • Non-Small-Cell Lung
    • Orange, California
    • +31 more
    Dec 6, 2022

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    Advanced/Metastatic Solid Tumors Trial in Frankston, Nedlands, Beijing (EMB07)

    Not yet recruiting
    • Advanced/Metastatic Solid Tumors
    • Frankston, Victoria, Australia
    • +2 more
    Nov 3, 2022

    NSCLC Trial (AK119, AK112, Pemetrexed)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Nov 23, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

    Active, not recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +5 more
    • Laboratory Biomarker Analysis
    • +3 more
    • New Haven, Connecticut
    • +4 more
    Jan 27, 2023